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Background: It is accepted that a woman's lifetime risk of developing breast cancer after menopause is reduced by
early full term pregnancy and multiparity. This phenomenon is thought to be associated with the development and
differentiation of the breast during pregnancy.
Methods: In order to understand the underlying molecular mechanisms of pregnancy induced breast cancer
protection, we profiled and compared the transcriptomes of normal breast tissue biopsies from 71 parous (P) and 42
nulliparous (NP) healthy postmenopausal women using Affymetrix Human Genome U133 Plus 2.0 arrays. To validate
the results, we performed real time PCR and immunohistochemistry.
Results: We identified 305 differentially expressed probesets (208 distinct genes). Of these, 267 probesets were up-
and 38 down-regulated in parous breast samples; bioinformatics analysis using gene ontology enrichment revealed
that up-regulated genes in the parous breast represented biological processes involving differentiation and
development, anchoring of epithelial cells to the basement membrane, hemidesmosome and cell-substrate junction
assembly, mRNA and RNA metabolic processes and RNA splicing machinery. The down-regulated genes represented
biological processes that comprised cell proliferation, regulation of IGF-like growth factor receptor signaling,
somatic stem cell maintenance, muscle cell differentiation and apoptosis.
Conclusions: This study suggests that the differentiation of the breast imprints a genomic signature that is centered
in the mRNA processing reactome. These findings indicate that pregnancy may induce a safeguard mechanism at
post-transcriptional level that maintains the fidelity of the transcriptional process.
Keywords: Gene expression profiling, Pregnancy, Breast morphology, Breast differentiation, Parous and nulliparous
breast transcriptome, Breast cancer risk, Normal breast transcriptome, Bioinformatics.Background
Epidemiological data from various parts of the world
have consistently shown that early full term pregnancy
and multiparity are associated with breast cancer risk
reduction in postmenopausal women [1-3], whereas late
pregnancy and nulliparity are associated with increased
risk [4]. It has been postulated that the mechanism of
pregnancy-induced protection is mediated by changes* Correspondence: Jose.Russo@fccc.edu
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reproduction in any medium, provided the orin environmental settings [5], and/or alterations in the
immunological profile of the host [6]. Animal studies of
the differentiation of the breast [7-9] under the influence
of the complex hormonal milieu created by two newly
formed endocrine organs, the placenta and the fetus [10],
have unraveled the morphological, functional, genomic
and transcriptomic changes that ultimately result in the
induction of a permanent and specific profile that serves
as an indicator of reduced cancer risk [11,12]. There is
some evidence supporting the concept that the degree
of differentiation acquired through an early pregnancy
changes the genomic signature that differentiates the
lobular structures of parous from that of nulliparous. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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characterizing the molecular basis underlying the mech-
anism of pregnancy-induced protection [3,11,12,14,18].
One way to assess whether a specific genomic finger-
print is permanently imprinted in the breast by a full
term pregnancy (FTP) is to compare the transcriptomic
profiles of breasts from parous and nulliparous women.
We have used a genome-wide approach to identify long-
term genomic changes associated with FTP by study-
ing breast core needle biopsies (CNBs) obtained from
an ethnically homogeneous population of healthy post-
menopausal volunteers residing in Norrbotten County,
Sweden. We previously reported on the genes differen-
tially expressed in parous and nulliparous women using
a discovery/validation approach [19]. In this paper, we
describe the transcriptomic differences that were found
between the breasts of parous and nulliparous women.
In order to gain more statistical power in understanding
the biological meaning of the transcriptomic differences,
in this study the data from the discovery and validation
phases were pooled and mined. Furthermore to mine the
data depending on gravida status, we stratified the anal-
yses depending on gravida status to identify importance
of full-term pregnancy. Our results suggest that the dif-
ferentiation of the breast induced by pregnancy imprints
a genomic signature that can be detected in postmeno-
pausal women, thus contributing to the establishment
of the molecular basis of the protection against breast
cancer conferred by parity.
Methods
To determine whether the pattern of gene expression dif-
fered between nulliparous and parous postmenopausal
women, breast tissue was collected from volunteering
healthy women residing in Norrbotten County, Sweden,
an ethnically homogeneous population of Swedish or
Finnish ancestry [19]. A total of 389 women from a
group who had received normal mammograms within
the year prior to enrollment were initially interviewed
between September 2008 and May 2009. 255 women
fulfilled the eligibility criteria and signed an informed
consent to participate in the study and to donate breast
tissues in the form of core needle biopsies (CNB), and
blood. We previously described various criteria that were
used in determining the eligibility of those included in
this study [19], such as women between 50 and 69 years
of age, postmenopausal; i.e., lack of menstrual periods for
12 preceding months and elevated circulating levels of
follicle stimulating hormone (FSH) (40–250 IU/L).
Based on reproductive history, eligible subjects were
categorized as either parous or nulliparous. The parous
group (P) included all women who had been pregnant
(Gravida) one or more times and had delivered (parous)
one or more live children. The nulliparous group (NP)included both nulligravida women who had never
become pregnant and therefore never had a full term
delivery, and women who had become pregnant one or
more times (G≥1) but never completed a FTP, identified
as nulligravida nulliparous (NN) and gravida nulliparous
(GN), respectively. Both NN and GN women were con-
sidered as a single group (NP) for most analyses, unless
indicated otherwise. The study protocol number 08-020M
was approved by the Regional Ethical Review Board at the
University of Umeå, Sweden. The study protocol number
02–829 was approved by the Institutional Review Board
of Fox Chase Cancer Center, Philadelphia, USA.
Data and sample collection
All eligible subjects signed an informed consent and
completed a questionnaire that collected data on rep-
roductive history, medical history, family background of
cancer, use of tobacco, oral contraceptive (OC), hormone
replacement therapy (HRT), and/or other medications.
Breast core needle biopsies (CNBs) with 14 Gauge
BARD® MONOPTY® disposable core biopsy instrument
(Bard Biopsy Systems, Tempe, AZ) were performed by an
experienced physician at the Mammography Department
at Sunderby Hospital, Luleå, Sweden. Three to five CNBs
were taken free hand from the upper outer quadrant
of either right or left breast; one core was fixed in 70%
ethanol for histopathological analysis and the remaining
cores were placed in RNAlater® (Ambion, Austin, TX)
solution for subsequent RNA extraction for genomic
analysis. In addition to breast tissue samples, each par-
ticipant provided blood and saliva samples that were
stored at Umeå University at −20°C for subsequent labo-
ratory analyses [19].
RNA isolation
Total RNA from CNB specimen was isolated using
the Qiagen Allprep RNA/DNA Mini Kit according
to manufacturer's instructions (Qiagen, Alameda, CA,
USA). The quantity of total RNA obtained from every
specimen ranged from 150ng to 4μg, as determined using
NanoDrop v3.3.0 (NanoDrop Technologies, Wilmington,
DE); RNA quality was assessed using an Agilent 2100
Bioanalyzer (Agilent Technologies, CA, USA).
Microarray analysis
The GeneChip Expression 3’-Amplification Two-Cycle
cDNA Synthesis Kit (Affymetrix, Santa Clara, CA) was
used to prepare the cRNA for hybridization following the
manufacturer’s protocol. The samples were hybridized to
Affymetrix HG_U133 Plus 2.0 oligonucleotide arrays.
113 chips (71 parous, 42 nulliparous) satisfied quality
control thresholds based on standard Affymetrix quality
control measures and graphical criteria based on probe-
level model (PLM) analysis as implemented in the
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were pre-processed using RMA [20]. To account for
between-batch variability in the arrays, the data were
adjusted using ComBat [21]. After filtering, 18,694 pro-
besets remained for further analysis.
To identify differentially expressed probesets, we
used the limma package [22,23] implemented in the
R/Bioconductor platform [24]. False Discovery Rates (FDR)
were calculated using the Benjamini-Hochberg method
[25]. In selecting probesets for downstream analysis, we
used both a p-value of 0.001 from the empirical Bayes
moderated t-statistics, and a minimum log2 fold-change
of 0.3 threshold as criteria of significance, unless other-
wise noted. A clustered heatmap of samples and selected
genes was generated using the RMA expression values,
uncentered Pearson correlation as a similarity measure
and average linkage (Figure 1). The microarray data of
this study have been submitted to the Gene Expression
Omnibus database (GSE26457).
Mining for functional categories and pathways
We applied data mining methods to identify enriched
biological processes and pathways. Gene ontology (GO)
functional categories enriched in differentially expressed
genes were identified using conditional hypergeometric
tests in the Bioconductor GOstats package. We carried
out this analysis independently for up and down regulated
genes while selecting the genes represented on U133plus2
chip as gene universe. An enrichment p-value cut off of
0.01 was used to select GO terms.
To identify pathways and associations to other previ-
ously described datasets, Gene Set Enrichment Analysis
(GSEA) [26] was performed. Since we were interested in
finding pathways and co-regulated genes, we expanded
the list of differentially expressed genes by relaxing the
p-value to 0.01 and did not apply any fold change filter.
Pathways obtained from MSigDB (database of gene sets
provided by GSEA) were tested for enrichment. Default
parameters were chosen, except that in the case of genes
with multiple probesets, only the probeset with maxi-
mum expression intensity was considered for analysis.
Validation through real time RT-PCR
Total RNA was reverse-transcribed (RT) using MMLV
reverse transcriptase (Ambion, Austin, TX) and anchored
oligo-dT. Real-time Taqman PCR Assays-on-Demand
were run using Universal PCR master mix (Applied Bio-
systems, Foster City, CA) on a 7900 HT instrument.
For each gene, the log2 fold change between parous and
nulliparous samples was estimated as the difference in
median Ct values. To assess the statistical significance
of the differences, two-sample Wilcoxon tests were per-
formed, and comparisons with p-value <0.05 were con-
sidered statistically significant. For comparison with themicroarray study, log2 fold changes were estimated as
the differences in median batch-adjusted RMA normal-
ized gene expression intensities in the same subset of
28 samples.
Histopathological and immunohistochemical analyses
From each breast biopsy collected, one core was fixed
in 70% ethanol and processed for histopathological and
immunohistochemical (IHC) analyses following standard
procedures. IHC analysis for cyclin L2 (CCNL2) was per-
formed in 21 NP and 29 P CNBs tissues utilizing a poly-
clonal anti-human cyclin L2 (CCNL2) antibody (Novus
Biologicals, Cambridge, UK) at a concentration of 5μg/ml.
Reactions were performed using the MultiLink Detection
Kit for HRP/DAB and the i6000 automatic stainer (both
from Biogenex, San Ramon, CA). CCNL2 positive cells
were scored according to the intensity of brown nuclear
stain as negative (0), weakly positive (+) or strongly posi-
tive (++). Results were expressed as the percentage of
positive cells over total number of epithelial cells present
in ducts and lobules type 1 in each section.
Results
Volunteers included in the analysis
As described in Methods, the study participants con-
sisted of postmenopausal women that were grouped
according to their reproductive history into parous (P)
and nulliparous (NP). The nulliparous group included
both, nulligravida nulliparous (NN) and gravida nullipar-
ous (GN); both NN and GN women were considered
within the NP as a single group for most analyses, unless
indicated otherwise. CNBs were first analyzed histopatho-
logically in order to determine the adequacy of tissue,
presence of ductal and lobular structures and the charac-
teristics of the stroma. A total of 126 biopsies obtained
from 82 P and 44 NP women were eligible for final gen-
omic analysis. The group of nulliparous women was
58.9±5.2 years old and the group of parous women
was 59.6±5.8 years old and there were not statistic
differences among the two groups. Therefore a vari-
ation in age subsets was not detected in this study, and
altogether the data reflect a well controlled group of post-
menopausal women.
Genomic analysis
From the 126 samples hybridized to Affymetrix HG_U133
Plus 2.0 oligonucleotide arrays, 113 chips (71 P, 42 NP)
satisfied quality control thresholds. Using empirical Bayes
moderated t-statistics with p-value less than 0.001 and a
minimum log2 fold-change of 0.3 thresholds as criteria
of significance, we identified 305 differentially expressed
probesets (corresponding to 208 distinct genes) between
P and NP women (see Additional file 1: Table S1). Of
these, 267 were up-regulated and 38 were down-regulated
Figure 1 Hierarchical clustering of differentially expressed probesets in parous and nulliparous women. Red represents expression values
above the median across all samples, and green represents values below the median. In the two top-level clusters of samples, the right cluster is
composed mainly of parous samples and the left cluster is composed mainly of nulliparous samples. ‘U’ represents the intensity of up-regulated
probesets among parous samples whereas ‘D’ represents the intensity of down-regulated probesets. N represents Nulliparous and Y represents
Parous. A chi-square test of independence on parity status and sub-tree membership resulted in a p-value of 0.001.
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ferentially expressed genes, the parity status labels were
randomly permuted and the analysis was repeated 10,000
times. Over half of the permutations yielded either 0 or 1
differentially expressed gene, the 95th percentile of counts
was 15 differentially expressed genes, and only 8 out of
10,000 permutations yielded at least 305 differentiallyexpressed genes (i.e. p-value = 0.0008) suggesting the
differentially expressed gene signature does not arise
by chance. Hierarchical clustering of the differentially
expressed probesets (with no sample clustering) shows
the pattern of up and down regulated genes within each
group (see Additional file 1: Figure S1). To understand
the biological theme of the observed gene expression
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of microarray data.
Gene ontology (GO) enrichment analysis revealed
biological processes that were categorized into groups
including RNA metabolic processes, differentiation and
development of epidermis and ectoderm, and cell-
substrate junction assembly (Table 1), findings that are
in agreement with existing knowledge that pregnancy
hormones promote the differentiation of mammary epi-
thelial cells [3]. Highly represented in the parous breast
were biological processes involving both mRNA and
RNA metabolic processes and RNA splicing machinery.
Important genes that were up-regulated within these
categories were: RBMX, HNRNPA1, HNRNPA2B1,
HNRNPD, LUC7L3, PNN, PRPF39, RBM25, SFPQ,
SFRS1, SFRS5, SFRS7, PABPN1, and PRPF4B. Biological
processes such as differentiation and development of epi-
thelial and ectodermal cells were represented by the up-
regulation of COL7A1, KRT5, KRT15, LAMA3, LAMC2,
NTF4, and KLK7. We also found that genes which are
pivotal in two biological processes that are critical to the
anchoring of epithelial cells to the basement membrane,
hemidesmosome and cell-substrate junction assembly,
such as KRT5, LAMA3 and LAMC2, were up-regulated
in the P group (Table 1).
Among the down-regulated genes, insulin-like growth
factor 1 (IGF-1) was enriched in 19 biological processes
that comprised cell proliferation, regulation of IGF-like
growth factor receptor signaling, somatic stem cell main-
tenance, muscle cell differentiation and apoptosis, among
others. Other down-regulated genes were RALGAPA2,
SOX6, ABHD5, EBF1 and RASD1 (Table 1).
We used gene set enrichment analysis (GSEA) to com-
pare differentially expressed genes from this study to
3717 curated gene sets of specific pathways, processes
and profiles of previous profiling experiments obtained
through MsigDB [26]. Pathways enriched by up-regulated
genes included breast cancer estrogen signaling, cell
communication and mRNA processing (Table 2). The
breast cancer estrogen signaling pathway encompassed a
set of genes that were dysregulated in estrogen receptor
dependent breast cancers. Among these genes were
SCGB2A1, SCGB2A2, GATA3, TP53, TFF1, STC2,
SERPINB5 and SERPINA3. Since full-term pregnancy
involves the influx of several hormones including estro-
gen, we postulated that several down-stream targets of
estrogen would be co-regulated in parous subjects. Other
pathways that were enriched by up-regulated genes were
cell communication (DSC3 and KRT5) and the mRNA
processing reactome (Table 2). Of great interest was the
significant number of genes related to the mRNA proces-
sing reactome that were differentially expressed by parity.
This pathway was comprised of those genes involved in
key molecular mechanisms that encompass mRNA andpre-mRNA processing reactions, as well as splicing of
mRNAs, whose representative genes include METTL3,
HNRPD, HNRPA2B1, PABPN1, PRPF4B, SRSF7, CLK4,
and SFRS5. Among the key pathways that were enriched
by down-regulated genes the most significant ones were
the insulin signaling pathway, MAPK, cytokine-cytokine
receptor interaction and Wnt signaling pathways (Table 2).
Contribution of full-term pregnancy (FTP) to
transcriptomic changes
To investigate whether an incomplete pregnancy could
induce transcriptomic changes in the breast tissue, in the
nulliparous group (NP) we compared gene expression of
GN against NN. We did not find any significant differ-
ences in gene expression between these two subgroups.
Comparison between P and GN revealed that 12 genes
(18 probes) were differentially expressed (see Additional
file 1: Table S2). The comparison between P and NN
revealed that 125 genes (206 probes) (see Additional
file 1: Table S3) were differentially expressed, and among
these, 107 genes had been identified in the comparison P
vs. NP. These results suggest that in this study popula-
tion, FTP was required for inducing detectable changes
in the transcriptome.
Validation of microarray results
Due to limitation in availability of RNA required for gene
expression validation, the following genes were selected
based on statistical significance of differentially expressed
genes and their biological relevance: XIST, CREBZF,
CCNL2, AHSA2, CIRBP, PILRB, OXTR, TNMD and
SOX6 (Table 3). These genes displayed the same expres-
sion behavior in both microarray and real time RT-PCR.
XIST, CREBZF and CCNL2 were significantly (p<0.05)
up-regulated in the parous women. In addition, the level
of expression and localization of CCNL2 was verified by
immunohistochemistry in nulliparous and parous breasts
(Figure 2). CCNL2 protein was significantly overexpressed
in the nucleus of epithelial cells of lobules type 1 of the
parous breast (Figure 2 d,e,f ) when compared with similar
structures found in the breast of nulliparous women
(Figure 2 a,b,c). These observations confirm the local-
ization of this protein in the splicing factor compartment
(nuclear speckles) [27].
Discussion
The work reported here demonstrates that differentiation
of the breast induced by an early pregnancy imprints a
specific genomic signature that can be detected in post-
menopausal women. Using bioinformatics methods we
found transcriptomic differences between the breasts
of parous and nulliparous women. These differentially
expressed genes were used to identify enriched biological
processes and pathways. Enriched biological processes
Table 1 GO biological processes enriched for both up and down regulated genes between parous and nulliparous
breast samples
GO term ID GO term (p-value) Genes up-regulated in parous samples
GO:0007044 cell-substrate junction assembly (0.006) KRT5, LAMA3, LAMC2
GO:0007398 ectoderm development (0.002) COL7A1, KRT5, KRT15, LAMA3, LAMC2, NTF4, KLK7
GO:0008544 epidermis development (0.001) COL7A1, KRT5, KRT15, LAMA3, LAMC2, NTF4, KLK7
GO:0010160 formation of organ boundary(0.009) NTF4
GO:0031581 hemidesmosome assembly (0.000) KRT5, LAMA3, LAMC2
GO:0016071 mRNA metabolic process (0.000) CIRBP, RBMX, HNRNPA1, HNRNPA2B1, HNRNPD, LUC7L3, PNN, PRPF39,
RBM25, SFPQ, SFRS1, SFRS5, SFRS7, PABPN1, PRPF4B
GO:0006397 mRNA processing (0.000) RBMX, HNRNPA1, HNRNPA2B1, LUC7L3, PNN, PRPF39, RBM25, SFPQ,
SFRS1, SFRS5, SFRS7, PABPN1, PRPF4B
GO:0034059 response to anoxia (0.009) OXTR
GO:0016070 RNA metabolic process (0.006) DDX17, CHD2,C BX3, CIRBP, ZNF785, EZH2, L3MBTL, GATA3, RBMX,
ZNF789, HNRNPA1, HNRNPA2B1, HNRNPD, LUC7L3, PNN, PRPF39,
ZNF83, METTL3, CREBZF, RBM25, RBBP8, RPS24, CENPK, SFPQ, SFRS1,
SFRS5, SFRS7, ZNF814, ZNF207, PABPN1, RUNX3, FUBP1, PRPF4B, HNRPDL
GO:0006396 RNA processing (0.000) DDX17, RBMX, HNRNPA1, HNRNPA2B1, HNRNPD, LUC7L3, PNN, PRPF39,
RBM25, RPS24, SFPQ, SFRS1, SFRS5, SFRS7, PABPN1, PRPF4B, HNRPDL
GO:0008380 RNA splicing (0.000) RBMX, HNRNPA1, HNRNPA2B1, HNRNPD, LUC7L3, PNN, PRPF39, RBM25,
SFPQ, SFRS1, SFRS5, SFRS7, PABPN1, PRPF4B
GO term ID GO term Genes down-regulated in parous samples
GO:0032859 activation of Ral GTPase activity (0.003) RALGAPA2
GO:0021534 cell proliferation in hindbrain (0.005) IGF1
GO:0009441 glycolate metabolic process (0.001) IGF1
GO:0042692 muscle cell differentiation (0.006) IGF1, SOX6
GO:0051450 myoblast proliferation (0.003) IGF1
GO:0006654 phosphatidic acid biosynthetic process (0.005) ABHD5
GO:0031325 positive regulation of cellular metabolic process (0.005) EBF1, IGF1, ABHD5, SOX6
GO:0045821 positive regulation of glycolysis (0.006) IGF1
GO:0051006 positive regulation of lipoprotein lipase activity (0.006) ABHD5
GO:0042523 positive regulation of tyrosine phosphorylation of Stat5
protein (0.009)
IGF1
GO:0031329 regulation of cellular catabolic process (0.002) IGF1, ABHD5
GO:0043567 regulation of insulin-like growth factor receptor signaling
pathway (0.007)
IGF1
GO:0010660 regulation of muscle cell apoptosis (0.006) IGF1
GO:0032485 regulation of Ral protein signal transduction (0.003) RALGAPA2
GO:0010889 regulation of sequestering of triglyceride (0.006) ABHD5
GO:0033143 regulation of steroid hormone receptor signaling
pathway (0.010)
IGF1
GO:0090207 regulation of triglyceride metabolic process (0.008) ABHD5
GO:0043403 skeletal muscle tissue regeneration (0.009) IGF1
GO:0007264 small GTPase mediated signal transduction (0.005) IGF1, RASD1, RALGAPA2
GO:0035019 somatic stem cell maintenance (0.010) IGF1
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cesses, differentiation and development of epidermis and
ectoderm, and cell-substrate junction assembly; whereas
in the case of down-regulated genes the biological
processes that were enriched included IGF-like growthfactor signaling, somatic stem cell maintenance and
apoptosis. Pathways that were enriched by up-regulated
genes included breast cancer estrogen signaling, cell
communication and mRNA processing machinery.
Numerous pathways were enriched by down-regulated
Table 2 Enriched GSEA pathways and gene sets for both up- and down-regulated genes. ‘NES’ represents normalized
enrichment score





Breast cancer estrogen signaling 2.217 0.002 SCGB2A1, TFF1, SCGB2A2, SCGB1D2, STC2, GATA3, SERPINB5, SERPINA3, AZGP1, TP53,
CCNA2, CCNE2, EGFR, PTEN, DLC1, FHL5
HSA01430 cell communication 1.711 0.075 KRT15, DSC3, DSG3, KRT5, COL4A6, KRT17, KRT14, LAMC2, LAMA3, LAMB3, THBS3, LAMA5,
LAMC1, GJA4, LAMA4, VWF, COL4A1, COL4A2
MRNA processing reactome 1.626 0.093 METTL3, HNRPD, HNRPA2B1, PRPF4B, SFRS7, CLK4, SFRS5, PABPN1, CSTF3, HNRPU, RBM5,
SNRP70, SFRS14, SNRPA1, CLK2, NXF1, SFRS8, SFRS2, PTBP2, FUS, SFRS6, SFRS16, SF3B1,
HNRPA3, SNRPB, PRPF3, SFRS12, U2AF1, PHF5A, TXNL4A, CUGBP2





HSA04910 insulin signaling pathway −2.242 0.004 CALML3, SHC4, IKBKB, PKM2, PIK3CD, PHKA1, CALM1, CBL, MAPK9, GSK3B, SKIP, MAP2K1,
PIK3R3, CRK, IRS2, SORBS1, SOS1, PDE3A, PDE3B, PRKAR2B, MAPK10, PCK1
HSA04080 neuroactive ligand receptor
interaction
−2.148 0.007 NPY2R, OXTR, PARD3, GABBR1, LTB4R, NR3C1, EDNRA, EDNRB, EDG1, CALCRL, ADRB2,
AGTRL1, ADRA2A, GHR, PTGER3, ADRA1A
HSA04530 tight junction −2.053 0.012 CGN, INADL, EXOC3, LLGL2, PARD3, PARD6G, TJP1, EPB41L1, ZAK, PPP2R1B, PTEN, GNAI1,
RRAS2, CTNNA1, MAGI1, CLDN10
HSA04010 MAPK signaling pathway −2.018 0.013 NTF5, FGFR3, CACNA1D, RASGRP1, MAP3K14, TP53, CACNA1G, FAS, PDGFA, IKBKB,
CACNA2D2, DAXX, GNA12, MAPK9, EGFR, GADD45A, DUSP10, CHP, DUSP3, MAP2K1, CRK,
MEF2C, ZAK, EVI1, TGFBR1, SOS1, FGF10, RAPGEF2, RRAS2, RASGRF2, MAPK10, ACVR1C
HSA05210 colorectal cancer −1.972 0.013 TP53, IGF1R, FZD8, RALGDS, PIK3CD, FZD6, CYCS, MAPK9, EGFR, GSK3B, MAP2K1, PIK3R3,
TGFBR1, SOS1, TCF7L2, FZD4, MAPK10, ACVR1C
HSA04510 focal adhesion −1.913 0.016 PAK7, COL4A6, LAMC2, LAMA3, SHC4, PAK6, ITGA10, LAMB3, ITGA4, PDGFA, IGF1R, THBS3,
LAMA5, ZYX, PPP1R12A, ITGA2, PIK3CD, MAPK9, CAV1, EGFR, PARVA, GSK3B, LAMC1,
MAP2K1, PIK3R3, CRK, FLT1, FYN, CCND2, PTEN, LAMA4, SOS1, VWF, IGF1, CAV2, TLN2,
COL4A1, PDGFC, COL4A2, MAPK10
Integrin mediated cell adhesion KEGG −1.661 0.062 CAPN3, PAK6, ITGA10, ITGA4, ZYX, ITGA2, CAV1, MAP2K1, CRK, SORBS1, FYN, SOS1, CAV2,
TNS1, MAPK10
HSA04310 WNT signaling pathway −1.423 0.161 CSNK1A1, NFATC3, TP53, WNT5A, VANGL2, FZD8, FZD6, MAPK9, GSK3B, CHP, DAAM1,
DAAM2, SOX17, PPP2R1B, CCND2, TCF7L2, FZD4, MAPK10
ST INTEGRIN SIGNALING PATHWAY −1.400 0.160 PAK7, PAK6, ITGA10, ITGA4, ZYX, ITGA2, MAPK9, CAV1, CRK, ARHGEF7, FYN, PTEN, SOS1,
TLN2, MAPK10
HSA04060 cytokine cytokine receptor
interaction
−1.383 0.152 CXCL6, IL28RA, CCL5, IFNGR2, FAS, IL4R, TNFSF15, PF4V1, TNFRSF14, IL2RB, IFNAR1, EGFR,
LIFR, FLT1, BMPR2, TGFBR1, PDGFC, GHR, BMP2.
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Wnt and integrins signaling pathways, MAPK, cytokine-
cytokine receptor interaction, tight junction and focal
adhesion, all representing proteins that are highly
expressed in malignancies.Table 3 RT-PCR validation results
ABI assay Gene symbol Gene name
Hs00221881_m1 CREBZF CREB/ATF bZIP transcription factor
Hs00300535_s1 XIST X (inactive)-specific transcript (non-prot
Hs01085988_m1 CCNL2 Cyclin L2
Hs00902302_m1 AHSA2 AHA1, activator of heat shock 90kDa pr
Hs00154457_m1 CIRBP Cold inducible RNA binding protein
Hs00273801_m1 PILRB Paired immunoglobin-like type 2 recep
Hs00168573_m1 OXTR Oxytocin receptor
Hs00223332_m1 TNMD Tenomodulin
Hs00264525_m1 SOX6 SRY (sex determining region Y)-box 6The main components of the spliceosome machinery,
including RNA and proteins that undergo dynamic
changes during the splicing reaction, were up-regulated
in the parous breast. Among them were the heteroge-
neous nuclear ribonucleoproteins (HNRPs) that includeLog ratio p-value 95% Cl
1.59 0.000 [0.70, 2.54]
ein coding) 1.19 0.006 [0.37, 1.95]
0.75 0.030 [0.05, 1.42]
otein ATPase homolog 2 (yeast) 0.78 0.002 [0.34, 1.87]
0.46 0.019 [0.06, 0.94]
tor beta 1.86 0.002 [0.72, 3.11]
1.99 0.002 [0.89, 2.74]
−1.27 0.012 [−2.52, -0.11]
−0.59 0.118 [−1.215, 0.13]
Figure 2 Immunohistochemistry of cyclin-cyclin L2 protein (CCNL2) performed in paraffin embedded tissues of nulliparous and parous
samples. CCNL2 protein was overexpressed in the nucleus of epithelial cells of lobules type 1 in parous breast (d,e,f) when compared to
nulliparous women (a,b,c) (40X).
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which are implicated in the regulation of mRNA stability,
as well as other functions, such as mammary gland invo-
lution [29], negative regulation of telomere length main-
tenance [30], and regulation of mRNA trafficking from
the nucleus to distal processes in neural cells [31]. Al-
though further studies are needed to define their precise
functional role in the postmenopausal breast, we postu-
late that they may play an important regulatory function
as transcriptional regulators. In addition, post-
transcriptional methylation of internal adenosine residues
in eukaryotic mRNAs by METTL3 (methyltransferase
like 3), which is up-regulated in the parous breast, couldplay a role in the efficiency of mRNA splicing, transport
or translation in the differentiated breast epithelium.
Other members of the spliceosome complex are the pro-
teins encoded by the genes SF3B1, SFRS2, SFRS7, SFRS8,
SFRS14, SFRS16, SNRP70, SNRPB, SNRPA1, PRF3 and
PHF5A, all of which are overexpressed in the parous
breast. In the case of the small nuclear ribo-
nucleoproteins (snRNPs), there is evidence that they
suppress tumor cell growth and may have major implica-
tions as cancer therapeutic targets. The pre-mRNA spli-
cing factors are enriched in nuclear domains termed
interchromatin granule clusters or nuclear speckles.
Among the members of the splicing factor compartment
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mRNA splicing process and are located in the nuclear
speckles [32,33]. These two genes are up-regulated in the
parous breast and the CCNL2 protein is also overex-
pressed in the nucleus of breast epithelial cells. CCNL1
and CCNL2 are transcriptional regulators [32,33] that
modulate the expression of critical factors leading to cell
apoptosis, possibly through the Wnt signal transduction
pathway [34], a signaling pathway that is enriched by
down-regulated genes in the parous breast (Table 2). In
our previously published preclinical and clinical studies
[3,7,9,11], we have reported that pregnancy confers
protection from breast cancer development by induc-
ing gland differentiation, which imprints a specific and
permanent genomic signature in this organ. A similar
phenomenon was demonstrated in the breast of postme-
nopausal parous women characterized by fatty involution
[3]. We previously described a small case–control study
of transcriptomic analysis of normal breast tissues
obtained from parous and nulliparous women free of
breast pathology and parous and nulliparous women with
history of breast cancer that served as controls and cases,
respectively [3]. In order to investigate the degree of
commonality between the previous case–control and the
present study, we applied GO enrichment analysis to the
gene lists generated from both studies. We found that
processes involved in RNA metabolism and RNA proces-
sing were similar in both studies (see Additional file 1:
Table S4).
A number of non-coding RNAs that included XIST,
MALAT-1 (also called NEAT2) and NEAT1 were up-
regulated in the parous breast. XIST, which inactivates X
chromosome as an early developmental process, plays an
essential role in female mammals by providing dosage
equivalence between males and females. Up-regulation of
XIST occurs upon differentiation, whereas failure to ex-
press XIST is often seen in malignancies and in early em-
bryogenesis [35]. Our findings are supported by recent
reports that suggest that XIST is expressed in adult well-
differentiated cells in order to maintain gene repression
[35-39]. Oxytocin, a neurotransmitter that acts through
it specific receptor OXTR and is overexpressed during
lactation, up-regulates the expression of MALAT-1, a
highly conserved non-coding RNA [40,41]. Interestingly,
both MALAT1 and OXTR remain overexpressed in the
breast of postmenopausal parous women. NEAT1 and
NEAT2 localize to the periphery and to the interior the
spliceosome assembly factor SC35 domains or speckles.
Our observation that in breast epithelial cells CCNL2 is
highly enriched in nuclear speckles (Figure 2) indicates
that CCNL2 might colocalize with NEAT1 and NEAT2.
The down-regulation of NEAT1, NEAT2 and XIST in
the breast of nulliparous women, in whom this organ
never reached a stage of complete differentiation similarto that achieved after completion of pregnancy and lacta-
tion [42], suggests that the undifferentiated breast is not
actively involved in the RNA metabolism that is neces-
sary for maintaining a state of differentiation.
Although in this study we did not observe differential
expression in estrogen receptor between parous and
nulliparous breasts, several genes that are directly or
indirectly regulated by estrogen receptor were up- or
down-regulated in the parous breast and were found to
be enriched in the breast cancer estrogen signaling gene
set. Among them, GATA3, an important component of
this gene set, is crucial to mammary gland morphogen-
esis and differentiation of progenitor cells. GATA3 has
been suggested to be a tumor suppressor [43], a fact sup-
ported by the observations that induction of its expres-
sion in GATA3-negative undifferentiated carcinoma
cells is sufficient to induce tumor differentiation and
inhibition of tumor dissemination [44-46]. The down-
regulation of RASD1 (RAS, dexamethasone-induced 1),
a potential miR-375 target that negatively regulates ER
alpha expression in breast cancer further confirms that
the genes involved in the estrogen receptor regulated
pathways could be under permanent transcriptional
modification as a manifestation of a higher degree of cell
differentiation of the parous breast, in spite of the lack of
transcriptomic differences in the levels of the receptor
between parous and nulliparous breast tissues.
Cell communication, which is a key element in the
process of cell and organ differentiation, is well repre-
sented in the breast of parous women. The parous breast
exhibits up-regulation of desmocollin (DSC3), a calcium-
dependent glycoprotein that is a member of the desmo-
collin subfamily of the cadherin superfamily. Members of
this desmosomal family, along with the desmogleins, are
found primarily in epithelial cells where they constitute
the adhesive proteins of the desmosome cell-cell junc-
tion and are required for cell adhesion and desmosome
formation. In addition, the up-regulation of matrix Gla
proteins (MGP), laminins (LAMA3 and LAMC2) and
keratin 5 (KRT5) in the parous breast reflect the greater
differentiated state of the breast epithelial cells [47]. This
concept is supported by the observation that the loss of
Matrix Gla protein expression may be associated with
tumor progression and metastasis [48].
Our findings that insulin-like growth factor 1 (IGF-1)
is down-regulated in the parous breast is consistent with
published data reporting overall lower levels of IGF-1 in
parous than in nulliparous women [49] and support the
association of IGF1 with increased breast cancer risk
[50]. It is known that IGF-1 stimulates mitosis and inhi-
bits apoptosis, playing a significant role in signaling path-
ways involved in the pathogenesis of breast cancer. The
down regulation of IGF-1 in the parous breast, in asso-
ciation with the significant down-regulation of SOX6,
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miR-375 target that negatively regulates ER alpha expres-
sion in breast cancer [51], and RALGAPA2, could repre-
sent a significant driving force in the reduction of breast
cancer risk conferred by pregnancy.
Conclusions
In this study using a core needle biopsy of postmeno-
pausal breast parenchyma comprising of stroma and
lobular structures, we found a specific genomic signature
induced by FTP. This genomic signature suggests that
the differentiation process of breast cells is centered in
the mRNA processing reactome, which emerges as an
important regulatory pathway induced by pregnancy.
The biological importance of the differential expression
of genes that control the spliceosome could be an indi-
cation of a safeguard mechanism at post-transcriptional
level that maintains the fidelity of the transcriptional
process. In addition, the critical regulatory pre-mRNA
splicing mechanism could also regulate the expression of
specific genes controlling estrogen signaling pathways,
cell communication and differentiation, as well as path-
ways related to chromatin remodeling, altogether result-
ing in control of cell differentiation and breast cancer
prevention. Future studies are needed to confirm these
results, in particular studies focusing specifically on lobu-
lar epithelial cells selected using laser capture microdis-
section (LCM). Finally, digital transcriptome analysis
such RNA-Seq methods will help in understanding the
precise differentiation paradigms in parous breast tissue.
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